alexis klein on Muck Rack

alexis klein

As seen in: Cell Press

Get in touch with alexis

Contact alexis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study

|
By David Planchard, Nathalie Cozic, Maria Fernanda Mosele, Noemie Corcos, Loic Le Bescond, Yoann Pradat, Maria Rosa Ghigna, Ghada Nachabeh, Alexia Alfaro, Cyril Catelain, Bastien Job, Fathia Mami-Chouaib, Severine Badel, Stephanie Corgnac, Françoise Farace, Marianne Oulhen, Patricia L. Kannouche, Nathalie Droin, Marie Wislez, Christos Chouaid, Hubert Curcio, Sophie Cousin Verified, Celine Mascaux, Jacques Cadranel, Margaux Geier, Rasha Cheikh-Hussin, Pierre Guyader, Nicholas Signolle, Karine Godefroy, Hugues Talbot, Maria Vakalopoulou, Stergios Christodoulidis, Elsa Bernard, Yves Akoli Koudou, Valerie Camara, Abdelhafidh Belarkemi, alexis klein, Jean Philippe Morretton, Philip East, Rachel Chiaverelli, Ricardo Zwirtes, Stefan Michiels, Fabrice Barlesi, Fabrice André, Guillaume Montagnac, Barbara Pistilli
| Cell Press Verified
Keywords ADC Dato-DXd mechanism of action response resistance NSCLC TROP2 internalization Introduction In 2022, lung cancer was the most frequently diagnosed cancer, with about 2.5 million new cases, and the leading cause of cancer death, with 1.8 million deaths worldwide.1 Several targeting therapies have been developed and approved over the past years for the treatment of metastatic lung cancer, particularly for non-small cell lung cancer (NSCLC); however, only 35%–40% of patients with...
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified